Video Camera Endoscopy Technology in Probiotics Research
About the webinar
What can you expect of our webinars?
ON DEMAND WEBINAR | AVAILABLE NOW
Duration: 15 min
Abstract: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are commonly used worldwide, both as prescription-only medicines and as “over-the-counter” preparations. However, low dose use of NSAIDS, is associated with gastrointestinal (GI) injury. Strategies to prevent GI complications associated with NSAID use included are generally associated with undesired side effects, whereas live bacteria formulated as probiotics may offer a safe alternative to prevent or at least decrease negative side effects of NSAIDS such as Aspirin. Given that deleterious compositional changes to the microbiota, in addition to direct effects on mucus and epithelial tissue, may increase the risk of NSAID-enteropathy, the sponsor of the present clinical trial hypothesised that an intervention targeting microbiome-host interactions may offer an attractive, preventative strategy.
Their strain selection was based on the anti-inflammatory properties of certain bifidobacteria and experimental pre-clinical evidence for a role of bifidobacteria in NSAID-associated ulceration as well as unpublished pre-clinical screening data suggesting an efficacy potential of the specific strain belonging to this genus. In addition, another Bifidobacterium breve has been shown to express a pilus-associated protein (Tad E) in vivo, but not in vitro, which promotes colonic epithelial proliferation. It is described the development of a clinical model to assess the quantitative and time-resolved induction of small intestinal injury upon ASA administration.
The key goals:
- To investigate the ability of the probiotic strain to attenuate and/or reverse low-dose, long-term NSAIDs-induced deterioration of small intestinal mucosa tissue as assessed by capsule endoscopy in healthy volunteers.
- To investigate the ability of the probiotic strain to attenuate and reverse low-dose, long term NSAIDs-induced GI symptoms as assessed AUC ulcer number as well as assessed by AUC of pain syndrome score for GSRS.
- To investigate co-administration of the probiotic strain to low-dose, long term NSAIDs on changes in multiple biomarkers of general intestinal barrier function in blood and faecal samples.
ANDREA DOOLAN | CEO & Founder at Atlantia Clinical Trials
Andrea has over 20 years of experience in the industry. She has a BSc in Microbiology and Higher Diploma from NUIG. Her early career experience as Clinical Trials Coordinator for the Harvard AIDS Clinical Trials Group at Massachusetts General Hospital, Boston was formative in establishing her future professional direction. Thereafter, she returned to Ireland as Clinical Trials Manager with the APC Microbiome Ireland, University College Cork wherein she played a leading role in the development of Atlantia, fully transitioning the business out of UCC in 2013. Andrea was awarded the Matheson WMB Female Entrepreneur of the Year Award in 2018, in acknowledgment of her innovative business leadership skills.
Andrea leads Atlantia sales and operations from their headquarters in Cork, managing the US and Irish clinic sites and an expert team of medical professionals, nutritionists, business development, and operational personnel.